title: Prevention of erectile dysfunction after radiotherapy for prostate cancer.
abstract: With increasing scrutiny of prostate cancer (PCa) diagnosis and treatment, much attention has been given to the morbidity caused by radical prostatectomy (RP) and/or radiotherapy (RT). One of the most common side-effects of either treatment is erectile dysfunction (ED). Approximately, 40% of patients will experience ED after RT for PCa. The post-RT ED causes significant patient dissatisfaction with cancer treatment as well as decrease in patient and partner psychosocial function. To address this issue in patients undergoing RT, Pisansky et al. conducted a prospective, randomized, double-blinded, placebo-controlled trial to assess the efficacy of a phosphodiesterase enzyme-5 inhibitor (PDE5i), tadalafil, as a preventive measure for patients undergoing RT for PCa and found no difference in erectile function between the control and treatment groups.
authors.forename: Izak
authors.initials: I
authors.lastname: Faiena
authors.forename: Neal
authors.initials: N
authors.lastname: Patel
authors.affiliation: Division of Urology, Cooper Medical School of Rowan University, Camden, NJ, USA.
authors.forename: Allen D
authors.initials: AD
authors.lastname: Seftel
mesh_terms: D002243:Carbolines / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000517:prevention & control*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000532:radiotherapy*; D011832:Radiation Injuries / Q000517:prevention & control*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D002243:Carbolines; D014665:Vasodilator Agents